The National Institute of Health and Care Excellence (NICE) has recommended the use of ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for relapsed and refractory myeloma patients. This treatment will be made available through the Cancer Drugs Fund (CDF) to patients in England and Wales who have received 2 or 3 prior treatments. This…Details
New agents in the Treatment of Myeloma Bone Disease.
Ring ES et al. Calcif Tissue Int. 2017 Nov 2. doi: 10.1007/s00223-017-0351-7. [Epub ahead of print].
Ciprofloxacin versus Levofloxacin for prophylaxis during Hematopoietic Stem Cell Transplantation.
Copeland V et al. Clin Transplant. 2017 Oct 28. doi: 10.1111/ctr.13145. [Epub ahead of print].
Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low MultipleSolitary Plasmacytomas Harboring a 17p Deletion. Kitamura H et al. Intern Med. 2017 Nov 20. doi: 10.2169/internalmedicine.9446-17. [Epub ahead of print]. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic…Details
Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma. Postmus D et al. Oncologist. 2017 Oct 27. pii: theoncologist.2017-0257. doi: 10.1634/theoncologist.2017-0257. [Epub ahead of print]. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Jimenez-Zepeda VH et al. Leuk Lymphoma. 2017 Nov 21:1-7. doi:…Details
CD38 bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B cell malignancies. Green DJ et al.Blood. 2017 Nov 20. pii: blood-2017-09-807610. doi: 10.1182/blood-2017-09-807610. [Epub ahead of print]. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Prabhu VV et al. Cell Cycle. 2017 Nov 20:1-29. doi: 10.1080/15384101.2017.1403689. [Epub ahead of print]. A review discussing elotuzumab…Details
Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. Bossuyt X et al.Leukemia. 2017 Nov 20. doi: 10.1038/leu.2017.335. [Epub ahead of print]. Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation. Cetin AE et al. Nat Commun. 2017 Nov 20;8(1):1613. doi: 10.1038/s41467-017-01593-2. Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma. Dalla Palma B et al. Br J Haematol. 2017 Nov…Details
Final analysis of survival outcomes in the randomized phase 3 FIRST trial. Facon T et al. Blood. 2017 Nov 17. pii: blood-2017-07-795047. doi: 10.1182/blood-2017-07-795047. [Epub ahead of print]. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Sivaraj D et al. Bone Marrow Transplant. 2017 Oct 30. doi: 10.1038/bmt.2017.208. [Epub ahead of print]. An overview of the…Details
Nonmyelomatous Ascites Resulting from the Increased Secretion of Vascular Endothelial Growth Factor in Multiple Myeloma. Maki H et al. Intern Med. 2017 Nov 20. doi: 10.2169/internalmedicine.8886-17. [Epub ahead of print]. Severe Hypoglycemia Caused by Lenalidomide. Przybylski DJ et al. Pharmacotherapy. 2017 Nov 20. doi: 10.1002/phar.2061. [Epub ahead of print]. Cardiovascular complications of multiple myeloma in the elderly. Mathur P et al. Expert Rev Cardiovasc Ther. 2017 Nov…Details
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Botta C et al. Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.336. [Epub ahead of print]. Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma. Gullà A et al.Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.334. [Epub ahead of print]. Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences…Details
This paper, written by a panel of experts from the International Myeloma Working Group (IMWG), reviews the available data on second primary malignancies in myeloma, and provides recommendations for treatment and management.